title: [Use of lysenyl-forte and methergoline in the therapy of hyperprolactinemic hypogonadism].
abstract: The paper is concerned with a study of the effectiveness of lysenyl-forte (Hemapol, Czechoslovakia) and methergoline (Carlo Erba, Italy) for therapy of patients with different types of hyperprolactinemic hypogonadism. Altogether 49 patients were investigated, of them 33 received lysenyl-forte at a dose of 0.6 mg/day and 16-methergoline at a dose of 12 mg/day for 3 months. A degree of galactorrhea, a menstrual cycle and the blood level of prolactin were assessed before and after therapy. A prolactin inhibiting effect of both drugs comparable with that of bromocriptine was noted. However a clinical effect and good tolerance were more frequently observed in this sampling in lysenyl therapy.
authors.forename: G A
authors.initials: GA
authors.lastname: Mel'nichenko
authors.forename: I I
authors.initials: II
authors.lastname: Dedov
authors.forename: E P
authors.initials: EP
authors.lastname: Gitel'
authors.forename: I A
authors.initials: IA
authors.lastname: Ilovaĭskaia
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D005260:Female; D005687:Galactorrhea / Q000209:etiology; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008090:Lisuride / Q000627:therapeutic use*; D008711:Metergoline / Q000627:therapeutic use*; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications; D011388:Prolactin / Q000037:antagonists & inhibitors; D015175:Prolactinoma / Q000097:blood / Q000150:complications
chemical_list: D008711:Metergoline; D011388:Prolactin; D008090:Lisuride
vernacular_title: Primenenie lisenila-forte i metergolina v lechenii giperprolaktinemicheskogo gipogonadizma.